Myasthenia gravis. A clinical analysis of the total material from Finland with special reference to endocrinological and neurological disorders.
D000367:Age Factors; D000549:Ambenonium Chloride / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003348:Cortisone / Q000627:therapeutic use; D048909:Diabetes Complications; D004185:Disability Evaluation; D004402:Dysautonomia, Familial / Q000150:complications; D005260:Female; D006261:Headache / Q000150:complications; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008572:Menarche; D001523:Mental Disorders / Q000150:complications; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy; D009461:Neurologic Manifestations; D011247:Pregnancy; D011248:Pregnancy Complications; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000150:complications; D012737:Sex Factors; D013959:Thyroid Diseases / Q000150:complications; D013997:Time Factors
D000549:Ambenonium Chloride; D011729:Pyridostigmine Bromide; D001379:Azathioprine; D003348:Cortisone